Voltin Conrad-Amadeus, Mettler Jasmin, Grosse Jirka, Dietlein Markus, Baues Christian, Schmitz Christine, Borchmann Peter, Kobe Carsten, Hellwig Dirk
Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne 50937, Germany.
Department of Nuclear Medicine, University Hospital Regensburg, Regensburg 93053, Germany.
Cancers (Basel). 2020 Mar 5;12(3):601. doi: 10.3390/cancers12030601.
Since the mid-1990s, F-fluorodeoxglucose (FDG)-positron emission tomography (PET) in combination with computed tomography has come to play a prominent role in the management of malignant lymphomas. One of the first PET applications in oncology was the detection of lymphoma manifestations at staging, where it has shown high sensitivity. Nowadays, this imaging modality is also used during treatment to evaluate the individual chemosensitivity and adapt further therapy accordingly. If the end-of-treatment PET is negative, irradiation in advanced-stage Hodgkin lymphoma patients can be safely omitted after highly effective chemotherapy. Thus far, lymphoma response assessment has mainly been performed using visual criteria, such as the Deauville five-point scale, which became the international standard in 2014. However, novel measures such as metabolic tumor volume or total lesion glycolysis have recently been recognized by several working groups and may further increase the diagnostic and prognostic value of FDG-PET in the future.
自20世纪90年代中期以来，氟脱氧葡萄糖（FDG）正电子发射断层扫描（PET）与计算机断层扫描相结合在恶性淋巴瘤的管理中发挥了重要作用。PET在肿瘤学中的首批应用之一是在分期时检测淋巴瘤表现，在这方面它已显示出高灵敏度。如今，这种成像方式也用于治疗期间，以评估个体化疗敏感性并据此调整进一步治疗。如果治疗结束时PET呈阴性，晚期霍奇金淋巴瘤患者在高效化疗后可安全地省略放疗。迄今为止，淋巴瘤反应评估主要使用视觉标准，如2014年成为国际标准的迪厄多内五点量表。然而，代谢肿瘤体积或总病变糖酵解等新指标最近已被多个工作组认可，未来可能会进一步提高FDG-PET的诊断和预后价值。
Zotero 插件